An extension study to assess BMD [bone mineral density] and bone turnover response to 5 mg daily risedronate [risedronic acid] treatment in women with PMO [postmenopausal osteoporosis].

Trial Profile

An extension study to assess BMD [bone mineral density] and bone turnover response to 5 mg daily risedronate [risedronic acid] treatment in women with PMO [postmenopausal osteoporosis].

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Sep 2011

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Adverse reactions
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 24 Mar 2010 Warner Chilcott added as trial sponsor,affiliate as reported by ClinicalTrials.gov.
    • 24 Mar 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 15 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top